127 related articles for article (PubMed ID: 15248476)
1. Brain tumor inhibition in experimental model by restorative immunotherapy with a corpuscular antigen.
Gangopaddhyay SK; Sarkar S; Begum Z; Chaudhuri S; Chaudhuri S
Indian J Exp Biol; 2003 Aug; 41(8):805-13. PubMed ID: 15248476
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic effects of T11TS/S-LFA3 against nitrosocompound mediated neural genotoxicity.
Mukherjee J; Sarkar S; Ghosh A; Duttagupta AK; Chaudhuri S; Chaudhuri S
Toxicol Lett; 2004 May; 150(3):239-57. PubMed ID: 15110076
[TBL] [Abstract][Full Text] [Related]
3. Sheep form of leucocyte function antigen-3 (T11TS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor. A new approach to biological response modifier therapy.
Sarkar S; Begum Z; Dutta S; Dutta SK; Chaudhuri S; Chaudhuri S
J Exp Clin Cancer Res; 2002 Mar; 21(1):95-106. PubMed ID: 12071536
[TBL] [Abstract][Full Text] [Related]
4. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
[TBL] [Abstract][Full Text] [Related]
5. Sheep erythrocyte demonstrated better effect than IL-2 and IFN-gamma as biological response modifier against glioma in experimental model.
Sarkar S; Ghosh A; Dutta S; Roy RU; Begum Z; Mukherjee J; Chaudhuri S; Chaudhuri S
Indian J Exp Biol; 2005 May; 43(5):414-9. PubMed ID: 15900905
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with T11TS / S-LFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status.
Mukherjee J; Ghosh A; Sarkar P; Mazumdar M; Banerjee C; Chaudhuri S
Anticancer Res; 2005; 25(4):2905-19. PubMed ID: 16080544
[TBL] [Abstract][Full Text] [Related]
9. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis.
Xiong Z; Gharagozlou S; Vengco I; Chen W; Ohlfest JR
Clin Cancer Res; 2008 Sep; 14(17):5484-93. PubMed ID: 18765540
[TBL] [Abstract][Full Text] [Related]
10. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
VanOosten RL; Griffith TS
Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of anti-tumor property of specific and non-specific BRMs in experimental gioma by assessing the microglial cell functional and phenotypic modulations.
Begum Z; Sarkar S; Mukherjee J; Ghosh A; Chaudhuri S; Chaudhuri S
Cancer Biol Ther; 2003; 2(4):356-63. PubMed ID: 14508105
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy of CNS malignancies.
Plautz GE; Shu S
Cancer Chemother Biol Response Modif; 2001; 19():327-38. PubMed ID: 11686021
[TBL] [Abstract][Full Text] [Related]
14. [The role of immune RNA in the immunotherapy of malignant brain tumor (author's transl)].
Nakamura O; Takakura K
No To Shinkei; 1982 Apr; 34(4):333-9. PubMed ID: 6178420
[TBL] [Abstract][Full Text] [Related]
15. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abulsamad K; Adams SL
Clin Immunol; 2008 Aug; 128(2):205-18. PubMed ID: 18511346
[TBL] [Abstract][Full Text] [Related]
16. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of sheep erythrocyte (SRBC)-induced pleurisy in non-sensitized mice by cyclophosphamide: demonstration of natural cell-mediated immune reactivity to SRBC.
Yamamoto S; Higuchi Y; Teshima H
Immunology; 1982 Sep; 47(1):31-40. PubMed ID: 7118162
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory and antitumor activity of triterpenoid fractions from the rhizomes of Astilbe chinensis.
Tu J; Sun HX; Ye YP
J Ethnopharmacol; 2008 Sep; 119(2):266-71. PubMed ID: 18692123
[TBL] [Abstract][Full Text] [Related]
19. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]